Clinical Trials Logo

Sarcopenia clinical trials

View clinical trials related to Sarcopenia.

Filter by:

NCT ID: NCT06274268 Not yet recruiting - Sarcopenia Clinical Trials

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

SARC-ONCO
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

NCT ID: NCT06272227 Not yet recruiting - Sarcopenia Clinical Trials

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

Start date: February 13, 2024
Phase: Phase 4
Study type: Interventional

This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group.

NCT ID: NCT06268171 Not yet recruiting - Sarcopenia Clinical Trials

Ultrasound Assessment of Rectus Femoris Cross-sectionnal Area Following Lung Transplantation

EchoSS-TP
Start date: March 4, 2024
Phase:
Study type: Observational [Patient Registry]

In France, the profile of patients receiving lung transplants has changed in recent years, mainly due to the advent of treatment for cystic fibrosis. This progress has led to an evolution in the patient profile, with an increase in cases of pulmonary fibrosis or COPD, and an increase in the average age of patients. In these older patients, sarcopenia, a condition characterized by loss of muscle mass, is a major concern, as it exacerbates morbidity and mortality. After transplantation, patients are at risk of developing neuromyopathy due to their hospitalization in intensive care. There is currently no effective preventive treatment for this condition, underlining the need for early rehabilitation strategies. The combination of sarcopenia and neuromyopathy diminishes their functional capabilities on discharge from the ICU. Muscle ultrasound, a simple, non-invasive technique, is already used to assess muscle function in intensive care patients. This study aims to evaluate the use of ultrasound to measure muscle loss in lung transplant patients, in particular by examining the rectus femoris muscle. Objectives include observing variations in the surface area of the rectus femoris muscle before and after transplantation, identifying factors influencing this variation, and exploring its relationship with post-transplant morbidity. In summary, this study seeks to better understand muscle loss in lung transplant patients using ultrasound, in order to identify risk factors and guide the development of post-transplant rehabilitation strategies.

NCT ID: NCT06261372 Completed - Clinical trials for Hemodialysis Patients With Sarcopenia

Mindfulness Meditation Combined With Progressive Muscle Relaxation Training for Uremic Sarcopenia

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

To study the effect of mindfulness meditation combined with progressive muscle relaxation training on clinical efficacy and quality of life in maintenance hemodialysis (MHD) patients with sarcopenia. Eligible sarcopenic patients in our hospital were randomly assigned to a control group (n = 24) and an intervention group (n = 25). The control group received conventional dialysis treatment, while the intervention group received mindfulness meditation combined with progressive muscle relaxation training during the interdialysis period in addition to conventional dialysis treatment. The effect of the intervention was evaluated after 12 weeks.To observe whether the combined intervention training can improve the motor ability and quality of life of patients with sarcopenia in a short period of time.

NCT ID: NCT06254573 Completed - Hemiplegia Clinical Trials

The Relationship Of Ultrasonographic Measurements With Sarcopenia in Stroke

Start date: May 10, 2022
Phase:
Study type: Observational [Patient Registry]

introduction:The aim of this study was to show the relationship of distal femoral cartilage and quadriceps thicknesses with functional status and presence of sarcopenia in ambulatory stroke patients with voluntary movement. Materials and Method: Forty-eight patients who were diagnosed with stroke due to cerebrovascular disease, had started voluntary movement, and had a motor recovery of 3 or above according to Brunnstrom's Staging were included in this cross-sectional study.

NCT ID: NCT06253273 Not yet recruiting - Fibromyalgia Clinical Trials

Functional Assessment of the Patient With Fibromyalgia and Its Relation to Health: Fibromyalgia and Sarcopenia

FIBYSAR
Start date: May 15, 2024
Phase:
Study type: Observational

Fibromyalgia is a chronic syndrome that causes fatigue, sleep disorders and generalized chronic pain in different parts of the body. This pathology is more prevalent in women and is generally not attributed to any specific cause. This observational study aims to describe some important and health-related factors in patients with fibromyalgia. Participants will have to fill out questionnaires related to sleep, anxiety, impact of the disease and sarcopenia index, and will then take tests related to grip strength for the upper limbs and dynamometry in the lower limbs. We will also employ the use of ultrasound to evaluate architectural measurements. Last but not least, we cannot forget the pain measurements that are so necessary in this study population.

NCT ID: NCT06248437 Completed - Sarcopenia Clinical Trials

Prototype of Innovative Food Product to Improve Respiratory and Peripheral Muscle Function in Humans

HIC1
Start date: March 30, 2019
Phase:
Study type: Observational

HIC1® compound has a presence in the form of a gel, which facilitates its oral intake (direct or diluted with water) and also administration through gastrostomy tubes or nasogastric tubes. All received a dose of 30 grams of gel.

NCT ID: NCT06238206 Completed - Stroke Clinical Trials

What User-requirements Need to be Considered When Developing a Lower-limb Exoskeleton? A Qualitative Study.

Start date: January 17, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to identify the needs and requirements of end-users regarding the implementation of a lower-limb exoskeleton in a remote home setting. The end-users include older adults with sarcopenia, post-stroke individuals and physiotherapists. The main question it aims to answer is: • What are the needs and requirements of the end-user population when developing a lower-limb exoskeleton that can be implemented in a remote home setting? Participants will engage in three separate focus group sessions, in which they will discuss the predetermined topics. Interactions between the participants will be guided by open questions.

NCT ID: NCT06235476 Not yet recruiting - Sarcopenia Clinical Trials

Protein Intake and Exercise-induced Muscle Damage

PROMO
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the effect of different protein-enhancement strategies versus carbohydrate control on exercise-induced muscle damage in physically active older adults. The main question it aims to answer is: What is the effect of three different protein-enhancement strategies (whey protein (WP), mixed plant-based protein (MPP), and use of protein-rich food products (PFP) on exercise-induced muscle damage in older adults compared to isocaloric carbohydrate control? Participants will: - Use a protein-enhancement strategy (WP, MPP or PFP) or carbohydrate control for a total of 5 weeks; - Participate in a single walking bound (30/40/50 km) two weeks after the start of the study; - Participate in a consecutive walking bound (4 days of 30/40/50 km) in the last week of the study period; - Complete different questionnaires and give blood samples to test for muscle damage.

NCT ID: NCT06231420 Enrolling by invitation - Sarcopenia Clinical Trials

Daily Step Count Using Pedometer for Sarcopenic Management in Patient With Cirrhosis: Randomized Controlled Trial

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of clinical trial is to compare using pedometer in sarcopenic cirrhotic patients. The main questions it aims to answer are: 1. Did the encourage using pedometer group had higher change of skeletal muscle index (SMI) than discourage using pedometer group? 2. How many of patients who had sarcopenic improvement in both groups at 6 months after enrollment? 3. What is the mortality rate and hospital admission in both groups at 12 months after enrollment?